AGXT2 has not been previously described as a gene that confers increased susceptibility for MMD, and the identification of this gene through an unbiased analysis (de novo analysis) thus corroborates the hypothesis of NO pathway involvement in MMD pathophysiology. Here, AGXT2 is linked to multiminicore myopathy.